Immunocompromised animal models for the study of antibiotic combinations

Area of Science:

• Infectious Diseases
• Pharmacology
• Microbiology

Background:

• Beta-lactam and aminoglycoside antibiotic combinations are often superior to monotherapy for Pseudomonas aeruginosa and Klebsiella pneumoniae infections in neutropenic animal models.
• Limited data exist on double beta-lactam combinations, with no clear benefit shown over single beta-lactam treatment for gram-negative infections.

Purpose of the Study:

• To evaluate the efficacy of combined antibiotic therapy versus single-drug treatment in various experimental infection models.
• To assess the role of in vitro synergism in predicting in vivo efficacy of combination antibiotic therapy.

Main Methods:

• Utilized various animal models, including neutropenic models for P. aeruginosa and K. pneumoniae, and experimental endocarditis models for Staphylococcus aureus, Streptococcus viridans, and Streptococcus faecalis.
• Compared the efficacy of combined beta-lactam/aminoglycoside therapy with single beta-lactam or aminoglycoside treatments.
• Correlated in vitro antibiotic synergism data with in vivo therapeutic outcomes.

Main Results:

• Combined beta-lactam/aminoglycoside therapy demonstrated clear advantages over single-drug treatments in both gram-negative and gram-positive infections.
• In P. aeruginosa infections, combination therapy not only increased bacterial killing but also prevented the emergence of small colony variants, a cause of treatment failure with aminoglycosides alone.
• In vitro synergism generally predicted enhanced in vivo efficacy, while lack of synergism correlated with no improvement in therapeutic outcomes.

Conclusions:

• Combined beta-lactam and aminoglycoside antibiotic therapy is highly effective for treating gram-negative and gram-positive bacterial infections in vivo.
• Animal models are crucial for understanding antibiotic efficacy, revealing benefits not always apparent from in vitro studies alone.
• In vitro synergism is a reliable predictor of enhanced in vivo efficacy for antibiotic combinations, guiding clinical trial design.